Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Income towards Parent Company: 2023-2025

Historic Income towards Parent Company for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$60.1 million.

  • Immunome's Income towards Parent Company fell 19.03% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of -$305.8 million for FY2024, which is 179.19% down from last year.
  • Per Immunome's latest filing, its Income towards Parent Company stood at -$60.1 million for Q3 2025, which was down 29.39% from -$46.5 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Income towards Parent Company ranged from a high of -$4.5 million in Q1 2023 and a low of -$132.3 million during Q1 2024.
  • For the 3-year period, Immunome's Income towards Parent Company averaged around -$51.5 million, with its median value being -$46.5 million (2025).
  • In the last 5 years, Immunome's Income towards Parent Company tumbled by 2,859.05% in 2024 and then surged by 66.26% in 2025.
  • Quarterly analysis of 3 years shows Immunome's Income towards Parent Company stood at -$94.7 million in 2023, then grew by 12.34% to -$83.0 million in 2024, then fell by 19.03% to -$60.1 million in 2025.
  • Its Income towards Parent Company was -$60.1 million in Q3 2025, compared to -$46.5 million in Q2 2025 and -$44.6 million in Q1 2025.